A Phase 3 Study to Assess the Immunogenicity, Safety, and Consistency of Lot Manufacture of Ross River Virus (RRV) Vaccine in Healthy Male and Female Subjects 16 Years of Age and Older

Trial Profile

A Phase 3 Study to Assess the Immunogenicity, Safety, and Consistency of Lot Manufacture of Ross River Virus (RRV) Vaccine in Healthy Male and Female Subjects 16 Years of Age and Older

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2015

At a glance

  • Drugs Ross River virus vaccine (Primary) ; Aluminium hydroxide
  • Indications Ross River virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT01242670).
    • 07 Oct 2011 Planned end date changed from 1 Aug 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 07 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top